BioCardia Files 8-K: Other Events Reported
Ticker: BCDA · Form: 8-K · Filed: Aug 28, 2024 · CIK: 925741
| Field | Detail |
|---|---|
| Company | Biocardia, Inc. (BCDA) |
| Form Type | 8-K |
| Filed Date | Aug 28, 2024 |
| Risk Level | medium |
| Pages | 1 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.001 B |
| Sentiment | neutral |
Sentiment: neutral
Topics: 8-k, other-events
Related Tickers: BCDA
TL;DR
BCDA filed an 8-K for 'Other Events' - details TBD.
AI Summary
BioCardia, Inc. filed an 8-K on August 28, 2024, to report other events. The filing does not contain specific details about the nature of these events, dollar amounts, or definitive dates beyond the filing date itself.
Why It Matters
This filing indicates BioCardia has reported an event to the SEC, but the lack of specific details means investors cannot immediately assess its impact.
Risk Assessment
Risk Level: medium — The filing is an 8-K for 'Other Events' without specific details, creating uncertainty for investors.
Key Players & Entities
- BioCardia, Inc. (company) — Registrant
- August 28, 2024 (date) — Date of earliest event reported
- Delaware (jurisdiction) — State of incorporation
- 001-38999 (filing_number) — Commission File Number
- 23-2753988 (irs_number) — IRS Employer Identification No.
- 320 Soquel Way Sunnyvale (address) — Principal executive offices
- California (state) — Principal executive offices
- 94085 (zip_code) — Principal executive offices
- ( 650 ) 226-0120 (phone_number) — Registrant's telephone number
FAQ
What specific event(s) are being reported under 'Other Events' in this 8-K filing?
The filing does not specify the nature of the 'Other Events' beyond stating that they are being reported.
When was the earliest event reported in this 8-K filing?
The earliest event reported was on August 28, 2024.
What is BioCardia, Inc.'s state of incorporation?
BioCardia, Inc. is incorporated in Delaware.
What is the Commission File Number for BioCardia, Inc.?
The Commission File Number for BioCardia, Inc. is 001-38999.
What is the principal executive office address for BioCardia, Inc.?
The principal executive office address is 320 Soquel Way, Sunnyvale, California 94085.
Filing Stats: 386 words · 2 min read · ~1 pages · Grade level 10.9 · Accepted 2024-08-28 17:12:58
Key Financial Figures
- $0.001 B — ch registered Common Stock , par value $0.001 BCDA The Nasdaq Capital Market Indicat
Filing Documents
- bcda20240827_8k.htm (8-K) — 20KB
- 0001437749-24-027952.txt ( ) — 148KB
- bcda-20240828.xsd (EX-101.SCH) — 3KB
- bcda-20240828_def.xml (EX-101.DEF) — 11KB
- bcda-20240828_lab.xml (EX-101.LAB) — 15KB
- bcda-20240828_pre.xml (EX-101.PRE) — 11KB
- bcda20240827_8k_htm.xml (XML) — 3KB
01 Other Events
Item 8.01 Other Events. BioCardia, Inc. (the "Company") was notified by the Food and Drug Administration (the "FDA") that the FDA has cleared the Company to market its Morph DNA Steerable Introducer product family, subject to the general controls provisions of the Federal Food, Drug and Cosmetic Act.
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. BIOCARDIA, INC. /s/ Peter Altman, Ph.D. Peter Altman, Ph.D. President and Chief Executive Officer Date: August 28, 2024